ACE inhibitors and their influence on inflammation, bronchial reactivity and cough.
Orally active angiotensin converting enzyme (ACE) inhibitors have been successfully used in the treatment of congestive heart failure and hypertension. However, adverse skin reactions, such as angioneurotic oedema have been reported following such medication. Furthermore, these drugs have been associated with a persistent dry cough in subjects without previous known bronchial hyper-reactivity. There is reason to believe that an ACE inhibitor-induced cough is due to an irritant inflammatory state in the airways of susceptible individuals and that this might have pathophysiological features in common with the cough seen as an early symptom of asthma. All inflammatory responses--wheal and flare reactions, airway reactivity, and infiltration by neutrophils and eosinophils--were enhanced by ACE inhibitors in a dose-dependent manner. Other ACE inhibitors might have different proinflammatory profiles.
Andersson
R G
RG
Department of Pharmacology, University Hospital, Linköping, Sweden.
Persson
K
K
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000818:Animals; D001985:Bronchial Provocation Tests; D001991:Bronchitis / Q000139:chemically induced*; D003371:Cough / Q000139:chemically induced*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D003875:Drug Eruptions / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007274:Injections, Intraperitoneal; D007428:Intradermal Tests; D008297:Male; D008875:Middle Aged
D000806:Angiotensin-Converting Enzyme Inhibitors